IRVINE, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that the University Medical Center of the Johannes Gutenberg University in Mainz, Germany has completed its clinical installation of Masimo noninvasive and continuous hemoglobin (SpHb) technology in their ORs, ICUs and EDs, as part of their efforts to improve patient care.
According to clinicians at the University Medical Center Mainz, their 57 Masimo Radical-7(R) Pulse CO-Oximeters with continuous and noninvasive hemoglobin are already providing significant clinical advantages and patient care benefits by allowing them to more effectively manage blood transfusions, identify internal bleeding sooner, and detect and treat chronic or acute anemia earlier - all of which may help save lives and improve patient outcomes.
Christian Werner, M.D., Chair of the Department of Anesthesiology at the University Medical Center Mainz, stated, "Masimo noninvasive hemoglobin is an exciting novel technology with wide clinical applications, which may ultimately improve peri-operative outcome. Furthermore, noninvasive SpHb monitoring could also reduce overall treatment costs."
By choosing Masimo Radical-7 Pulse CO-Oximeters, Mainz clinicians have also gained all the benefits of Masimo SET Measure-Through Motion and Low-Perfusion pulse oximetry, proven superior in over 100 independent and objective clinical studies. Masimo Rainbow SET is the first and only technology platform capable of continuously and noninvasively measuring multiple blood constituents that previously required invasive procedures, including: hemoglobin (SpHbTM), oxygen content (SpOCTM) carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and PVITM for fluid responsiveness, in addition to oxyhemoglobin (SpO2), perfusion index (PI) and pulse rate.
Masimo Founder and CEO, Joe E. Kiani, stated, "This multi-department installation at a leading German hospital is a good example of the growing recognition and adoption of Masimo SpHb, which gives hospitals and clinicians the opportunity to advance clinical practice in a way that has the potential to transform healthcare delivery. We applaud University Medical Center Mainz for recognizing the value of SpHb and for leading the advancement of patient care with the deployment of Masimo rainbow SET across their ORs, ICUs and EDs."
The University Medical Center Mainz is a healthcare facility, as well as a research and teaching hospital that leverages state-of-the-art diagnostic and therapeutic procedures to optimize patient care. It consists of more than 50 specialist clinics, institutes and departments, as well as two central health-care facilities, a pharmacy and a transfusion center. The hospital has over 1,600 beds and treats approximately 61,000 in-patients and 217,000 out-patients every year.
About University Medical Center of the Johannes Gutenberg University Mainz
The 'University Medical Center Mainz' consists of more than 50 specialist clinics, institutes and departments as well as two central health-care facilities, a pharmacy and a transfusion center. All of these clinics and institutes work together on an interdisciplinary basis. The hospital has over 1600 beds and treats more than 61,000 in-patients every year. It also serves an additional 217,000 people per year on an out-patient basis. We define ourselves as the patients' best source for optimum patient care. In our work, we use state-of-the-art diagnostic and therapeutic procedures based on recent medical research. It is our goal to serve as optimally as possible by integrating our knowledge and experience into the excellent services we provide. We offer nearly every kind of clinical facility you might need. The University Medical Center offers health care to the highest university standard. In addition, we are not only a health-care center; but also a research and teaching hospital. These three pillars of medicine - clinical health care, medical education and research - are inseparable aspects of integrated health care. For more information, please visit: www.klinik.uni-mainz.de
Masimo (Nasdaq: MASI) develops innovative monitoring technologies that significantly improve patient care - helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low-Perfusion pulse oximetry, known as Masimo SET(R), which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET(R) Pulse CO-OximetryTM, a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHbTM), oxygen content (SpOCTM), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and PVITM, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results, risks related to our belief that the breakthrough blood constituent monitoring capabilities of Masimo Rainbow SET will allow clinicians to detect and treat life-threatening conditions earlier, risks related to our belief that Masimo noninvasive and continuous hemoglobin (SpHb) will provide sufficient sensitivity and specificity to instantaneously measure hemoglobin blood levels noninvasively and continuously to enable earlier identification of necessary blood transfusions, reduction in unnecessary transfusions and invasive tests, increased patient safety, and improved clinical outcomes, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Media Contacts: Dana Banks Masimo Corporation +1 (949) 297-7348
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.
Copyright©2009 PR Newswire.
All rights reserved